Biogen Announces Two New Nominees for Election to Board of Directors

• Nominees bring diverse business and public health experience key to Biogen’s mission to pioneer and lead in neuroscience
• Company thanks Director Robert W. Pangia as he retires from the Board

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the nomination of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the company’s board of directors at its 2021 annual meeting of stockholders, scheduled for June 2, 2021. Additionally, Robert W. Pangia, who has served on the board since 1997 and is Chair of the Compensation and Management Development Committee, will retire from the company’s board this year, effective at the annual meeting of stockholders.

Dr. Freire is President and Executive Director and member of the board of directors of the Foundation for the National Institutes of Health, a nonprofit organization committed to accelerating biomedical research and advancing breakthrough discoveries to fight critical diseases. Mr. Jones is the President and Chief Executive Officer and a director of CityLink Investment Corporation, a commercial real estate investment and development services firm that has earned national acclaim for developing complex private and public urban projects.

“Our board believes ensuring diverse perspectives, including a mix of skills, experience and backgrounds, is key to representing the interests of stockholders effectively,” said Stelios Papadopoulos, Ph.D., Biogen’s Chairman.

Dr. Papadopoulos continued, “On behalf of the board of directors and Biogen, I would like to thank Bob Pangia for his long-standing service. His active engagement, expertise and wise counsel have been invaluable in our efforts to serve the best interests of all of Biogen’s stakeholders. We wish him the best for the future.”

“I am pleased by the nomination of Maria and William. I look forward to the added fresh perspectives they will provide and working with them to optimize Biogen’s capital allocation for the benefit of all stockholders,” stated Alexander J. Denner, Ph.D., Chair of the Corporate Governance Committee. “With their nomination, we have taken another important step in the refreshment and diversification of the board.”

“We are excited to announce these nominations for election to Biogen’s board at an important time at Biogen,” said Michel Vounatsos, Biogen’s Chief Executive Officer. “Maria and William have diverse backgrounds spanning medical research, pharmaceuticals, business, not-for profit boards and public health. Their breadth of experience will be instrumental in our mission to discover, develop and deliver worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.”